RECOMMENDATIONS.CELIDA.CODEX.NETZWERK-UNIVERSITAETSMEDIZIN.DE\Therapeutic Anticoagulation Treatment with Nadroparin

CODEX+ CELIDA Recommendations
1.5.2 - ci-build

CODEX+ CELIDA Recommendations - Local Development build (v1.5.2) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

ActivityDefinition: Therapeutic Anticoagulation Treatment with Nadroparin (Experimental)

Official URL: https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommended-action/drug-administration-action/therapeutic-anticoagulant-nadroparin-administration				Version: 0.1
Active as of 2024-08-07			Responsible: NUM CODEX+ CELIDA	Computable Name: TherapeuticAnticoagulationPlanNadroparin

Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients with high risk (D-Dimer >= 2mg/l) with Nadroparin

Generated Narrative: ActivityDefinition TherapeuticAnticoagulationNMHNadroparin

url: ActivityDefinition Therapeutic Anticoagulation Treatment with Nadroparin

version: 0.1

name: TherapeuticAnticoagulationPlanNadroparin

title: Therapeutic Anticoagulation Treatment with Nadroparin

status: Active

experimental: true

subject: Patient

date: 2024-08-07 14:55:39+0000

publisher: NUM CODEX+ CELIDA

description:

Therapeutic Anticoagulation Treatment (NMH) for non-intensive care hospitalised COVID-19 patients with high risk (D-Dimer >= 2mg/l) with Nadroparin

kind: MedicationRequest

code: Administration of substance (procedure)

product: Nadroparin (substance)

dosage